The need for antifungal stewardship is gaining recognition with increasing incidence of invasive fungal infection (IFI) and antifungal resistance alongside the high cost of antifungal drugs. Following an audit showing suboptimal practice we initiated an antifungal stewardship programme and prospectively evaluated its impact on clinical and financial outcomes.
Introduction
Stewardship programmes are effective in reducing inappropriate antimicrobial use, improving patient outcomes and limiting emergence of resistance. 1, 2 Owing to the higher burden of bacterial infection, health policy has traditionally emphasized curtailing antibiotic resistance 3 and spread of hospital-acquired Clostridium difficile 4 and MRSA. 5 To date, implementation and evaluation of stewardship programmes has therefore largely focused on antibacterials. 6, 7 The complexity of managing invasive fungal infection (IFI) poses a challenge to antifungal stewardship (AFS). The number of high-risk immunosuppressed hosts is growing, which, coupled with poor local diagnostics and inadequate prescriber knowledge of IFI, results in high rates of inappropriate prescribing (25%-75% of prescriptions). [8] [9] [10] [11] This offers scope for specialist intervention. Stewardship may also help stem the emergence of antifungal resistance, 3, 6, 12 which poses an increasing threat to global food security and human health. 13 An audit of antifungal prescribing at our hospital in 2009 identified suboptimal post-prescription review and performance of azole therapeutic drug monitoring (TDM). Following the appointment of a consultant infectious diseases physician with an interest in IFI we implemented weekly AFS rounds, commencing in October 2010. Our aims were to optimize care of patients with IFI; stop unnecessary empirical treatment; de-escalate antifungal therapy V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. when possible; perform TDM appropriately; and reduce antifungal usage and expenditure, without compromising clinical outcomes or resistance rates.
To our knowledge, ours was the first dedicated AFS programme introduced in England. Six years later, just 11% (5/47) of English acute NHS trusts surveyed reported undertaking dedicated AFS. 7 Only a handful of reports on the effectiveness of AFS programmes in the USA and Europe have been published to date. [14] [15] [16] [17] [18] [19] A single report from a tertiary UK centre demonstrated a crude saving of £188000 in drug costs over a 1 year intervention period in 173 patients. 20 We present an evaluation of the effectiveness of our AFS programme (2010-16) based on comprehensive, prospectively collected clinical, microbiological and financial outcome data.
Patients and methods

Ethics
In keeping with St George's Hospital Ethics Committee policy and guidance from the National Research Ethics Committee, 21 no formal ethics approval was considered necessary as this was an audit of data collected during routine clinical activities.
Setting
St George's Hospital is a 1300 bed teaching hospital in south-west London providing secondary care to 0.5 million people and tertiary care services to 3.4 million people in south-east England. These include populations at risk of IFI: patients with acute leukaemia, autologous and allogeneic stem cell transplantation (n " 29/year in 2009, rising to 53 in 2016), renal dialysis and transplantation, inpatients in an 18 bed infectious diseases ward (admitting 100-120 HIV-infected patients per year) and three adult ICUs (general, cardiothoracic and neurosurgical; total bed expansion from 39 to 60 between 2010 and 2016). There is an infectious diseases consultation service for all inpatients with suspected or proven infection and those in an ICU. On-site IFI diagnostics include Candida speciation and fluconazole susceptibility testing, pneumocystis immunofluorescence (latterly PCR), twice-weekly azole TDM, same-day high-resolution chest CT and histopathology with fungal-specific stains [Grocott/Periodic acid-Schiff (PAS)]. Biomarker tests (galactomannan, b-D-glucan), fungal serology and PCR, mould identification and susceptibility testing are sent to the national reference laboratory in Bristol.
AFS strategies in place prior to initiation of stewardship rounds were antifungal guidelines (since 2005, updated annually) and formulary restriction (microbiology/infectious diseases authorization for off-guideline use of amphotericin, echinocandins, posaconazole and voriconazole since 2008).
Patient identification
All adult patients receiving antifungal therapy with amphotericin B (liposomal and conventional), echinocandins, intravenous fluconazole, flucytosine or voriconazole were identified through interrogation of pharmacy computer systems. Paediatric patients, those on standard oral prophylaxis (posaconazole and itraconazole) and outpatients (haematology day-care unit attendees excepted) were excluded. All patients identified were seen on a weekly stewardship ward round by an infectious diseases consultant and antimicrobial pharmacist, which incorporated reviewing medical notes, drug charts, laboratory tests and imaging. Cases were discussed with the clinical team whenever possible and recommendations for patient care documented in medical notes.
Data collection and classification
We prospectively recorded patient demographics, antifungal drug, indication for therapy (prophylaxis, empirical or targeted), site of infection, causative organism if identified, length of stay and in-hospital mortality in a Microsoft Excel (v2003) database. Recommendations made were also recorded and the antimicrobial pharmacist followed up patients to assess implementation.
Targeted therapy was defined as the administration of an antifungal drug by the treating clinicians to treat IFI suspected on the basis of typical symptoms or signs or results of laboratory tests or imaging. In neutropenic patients, empirical therapy was defined as antifungal drugs administered to febrile patients not responsive to broad-spectrum antibacterial therapy, without focal signs, symptoms or microbiological results suggestive of IFI. Pre-emptive therapy was not included as a category owing to the lack of routine biomarker screening of at-risk patients. In non-neutropenic patients, empirical therapy was defined as treatment initiated in critically ill patients with risk factors for invasive candidiasis in the absence of other known causes.
Based on all results, the final diagnosis of IFI was classified by the stewardship team as 'none', 'proven', 'probable' or 'possible' IFI based on European Organization for Research and Treatment of Cancer (EORTC) criteria. 22 
Antifungal consumption and expenditure data
Antifungal consumption data were extracted from pharmacy records (JAC medicines management system v4.47) and reported as DDDs 23 from 1 April 2009 to 30 September 2016. As the DDD for liposomal amphotericin (AmBisome V R ) has not been described, the average prescribed daily dose of 200 mg was used. Expenditure data are reported as cost of antifungals (inpatients and outpatients for all patient groups) issued from the pharmacy per month, based on the price paid by St George's hospital. To contextualize expenditure data, occupied bed days (OBDs) data were obtained for the trust as a whole and within the three adult ICUs, as well as the numbers of chemotherapy cycles and bone marrow transplants performed in adults over the period 2009-16.
Microbiological data
Candidaemia speciation and susceptibility results from 2008 to 2016 were extracted from the microbiology database. Speciation was by MALDI-TOF MS from 2012 and using the germ-tube test and API Candida (bioMérieux) prior to 2012. Candida fluconazole MIC testing was performed using Etest (bioMérieux) locally and by the reference laboratory for all antifungals for significant isolates. Persistent candidaemia (same Candida species cultured from a blood sample taken 30 days after the initial positive blood culture in a given patient) was analysed as a single episode, whereas episodes .30 days apart were defined as a recurrence and counted as two episodes.
Statistical analysis
Data were analysed using Microsoft Excel v2003. Continuous variables were compared using the t-test and categorical variables using the v 2 test in Prism v7 (GraphPad Software, CA, USA).
Results
Between 6 October 2010 and 30 September 2016 there were 512 antifungal prescriptions that triggered a review by the stewardship team in 428 patients (an additional 4 patients were reviewed at the request of the clinical teams). Four hundred and thirty-two patients were reviewed 769 times on 246 AFS rounds (median 3 per round, range 1-10). Median patient age was 56 years (range 16-93); 58% were male. Two-thirds of patients (n " 285, 66%) were seen once; 16% (n " 69) required three or more reviews (mainly those on targeted therapy). Seven patients died prior to Antifungal stewardship at St George's JAC review. Top specialties prescribing antifungals were haematooncology (n " 209, 41%), intensive care (n " 49, 9%; nonhaemato-oncology patients only), general surgery (n " 44, 9%) and infectious diseases (n " 39, 8%).
Indication for and appropriateness of antifungal prescribing (Table 1 and Figure 1) For 516 antifungal prescribing episodes reviewed, the most common drug initiated was AmBisome V R (181, 35%), followed by intravenous fluconazole (149, 29%) and the echinocandins (120, 23%). Of 212 patients receiving targeted therapy, 60% (n " 127) had proven IFI by EORTC criteria and 75% (n " 158) had proven, probable (n " 16) or possible (n " 15) IFI. In 40 cases, therapy was targeted at a positive culture from a non-sterile site. These were classified as either non-invasive fungal infection (n " 33) or fungal colonization, usually respiratory (n " 7). In 14 cases, patients with clinically significant infections failed to meet EORTC criteria.
In the case of empirical prescribing, 82% (150/183) of patients were subsequently found to have no evidence of IFI on clinical, microbiological and radiological criteria. Only 21 patients (11%) subsequently met criteria for proven, probable or possible IFI. Of 121 patients receiving non-standard prophylaxis, the majority (105, 87%) were haemato-oncology patients on primary prophylaxis (AmBisome V R n " 79; caspofungin n " 25, micafungin n " 1); 49 (47%) were deemed appropriate. Nine patients had antifungal prophylaxis switched or stopped prior to the AFS round. Switches in drug class (primarily to azoles) were recommended in 44 cases (AmBisome V R 28/79 and echinocandins 16/26) and stopping prophylaxis was recommended in 3 cases (2 caspofungin, 1 AmBisome V R ). The most common indication for AmBisome V R was concomitant vincristine chemotherapy for acute lymphoblastic leukaemia; for echinocandins it was adverse drug reactions.
Stewardship advice and acceptance (Table 2)
Advice was offered in two-thirds of reviews (494/767, 64%), with 136 reviews resulting in multiple suggested interventions. Advice was followed in 84% of evaluable recommendations (471/558). The most common advice, switching to an alternative drug (n " 122, 21%), had the lowest acceptance rate (85/118, 72%). Advice to stop antifungals (n " 85), define treatment duration (n " 71) or perform TDM (n " 68) was also common, with high acceptance rates (89%, 84% and 83%, respectively; Table 2 ).
The remaining 265 reviews required no intervention: 126 were on appropriate treatment, 57 were on prophylaxis as per trust policy (when azoles were contraindicated) and 82 patients had already had their antifungal therapy modified prior to the round (stopped in 55, switched in 27).
Of 138 patients prescribed empirical antifungal therapy who had no IFI, 62% (86) had their prescriptions stopped within 1 week, compared with 44% (8/18) in our pre-implementation 2009 audit (P " 0.15). De-escalation was performed when appropriate in 87% (26/30) compared with 50% (2/4) of patients pre- Final IFI diagnosis by indication for antifungal prescribing. Total: n " 183 empirical; n " 211 targeted; n " 121 prophylaxis. *Non-invasive fungal infections not meeting EORTC criteria: 4 Candida endophthalmitis diagnosed by ophthalmology, 2 mediastinitis post-oesophageal perforation, 8 candiduria with prosthetic material in situ, 2 mastoid osteomyelitis with Aspergillus from ear swab, 4 high-risk patients empirically treated for IFI too unwell to undergo diagnostics (CT scan), 2 semi-invasive pulmonary aspergillosis and 2 penetrating wounds from tree branches.
implementation (P " 0.004). TDM was performed when indicated by trust guidelines in 74% (51/69) versus 43% (10/23) of patients (P " 0.008) and results outside the therapeutic range were acted upon in 74% (14/19) of cases (0/2 pre-intervention).
Microbiological and clinical outcomes (Table 3) There were 131 proven IFIs. Microbiologically proven IFIs were diagnosed from blood (n " 63) and other sterile sites (n " 58). Nine IFIs were diagnosed on histology only and one by cryptococcal antigen in CSF. Candida albicans was the most commonly isolated pathogen, both from blood and other sterile sites (n " 59, 45%), followed by non-albicans Candida spp. (n " 44, 33%). The abdomen was the most common site of infection (40/102). Proven mould infection was rare (n " 13): 2 cases of invasive aspergillosis proven on culture only (prosthetic joint infection and discitis); 4 cases of aspergillosis and 1 of mucormycosis proven microbiologically and histologically; and 4 cases of invasive aspergillosis and 2 cases of mucormycosis diagnosed on histology alone. Figure 2 illustrates the number of candidaemia episodes and causative species distribution in adults and children during the preand post-AFS intervention period. Overall candidaemia numbers remained below the pre-intervention baseline of 30 per year. The proportion of candidaemias due to non-albicans species was similar pre-and post-intervention: it was 27% and 45% in the 2 years preceding the intervention and averaged 49% from 2010 to 2016 (range 33%-70%). In terms of susceptibility of Candida glabrata to echinocandins, the modal MIC value for 34 isolates tested at the reference laboratory between 2009 and 2016 was 0.125 (susceptible) for each 2 year period except for 2015-16, when it was 0.25 (intermediate), with no instances of echinocandin resistance to date. There were no reported candidaemia episodes due to Candida krusei.
Over 2010-16, 756 galactomannan tests were requested and sent to the reference laboratory, with a median (IQR) turnaround time (TAT) to result authorization of 13 (11) (12) (13) (14) (15) (16) (17) days. As a result of the intervention, the number of galactomannan tests increased from a baseline of 45 (2010) to 182 in 2016, increasing spending from £2025 to £8190 (total cost 2010-16, £34020). b-D-Glucan was less frequently requested, with 37 tests sent away over 6 years (cost £2183) and a similarly long TAT (median 12 days, IQR 9-14 days). For TDM tests, we were able to obtain data on the number and costs of tests done in 2015-17: 192, 301 and 112 tests, respectively, costing £26600 in total (mean annual spend £8867). Extrapolating the latter figure to the period 2010-16, the estimated mean annual laboratory spend was £14900.
Inpatient mortality (excluding patients on prophylaxis) was 26% (101/383), compared with 38% (19/50, P " 0.1) in the preintervention period. In the prospective cohort, mortality was similar in patients with proven/probable IFI compared with those without (42/150, 28%, versus 61/231, 26%, P " 0.7). Length of stay (median 34 days, range 1-315 days) did not alter significantly over the course of the intervention (28 days in years 1 and 6, peak 37 days in year 3). Length of stay was significantly higher for those with proven or probable IFI (47 versus 30 days, P , 0.0001).
Antifungal spending and consumption (Figure 3a and b)
Following implementation of our AFS programme, total antifungal expenditure (adult and paediatric, inpatient and outpatient) initially showed a downward trend, reducing by 26% in the first 3 years (from £0.98 million to £0.73 million). Expenditure then rose to £1.17-£1.4 million per year, a 20% increase compared with preintervention (2009-10). By comparison, NHS England data (P. Howard, NHS Improvement, personal communication) shows that national antifungal expenditure has increased significantly from £64.1 million to £94.2 million during the 5 year period 2011-16.
Independent of the AFS programme, changes in drug pricing impacted expenditure; anidulafungin was added to the formulary in April 2011 as the echinocandin of choice in non-haematooncology patients (28% reduction in price compared with caspofungin), posaconazole tablets were introduced in October 2014 (cost neutral compared with liquid) and micafungin became the echinocandin of choice for all patients in October 2015 (cost neutral compared with anidulafungin, 28% reduction in price compared with caspofungin), with a further 38% price reduction in October 2016.
Parallel to the changes in expenditure, antifungal consumption initially decreased from 30000 DDDs in 2009-10 to 22103 DDDs in 2011-12 (a 26% reduction) before steadily increasing to 33610 DDDs in 2016-17. All antifungal drugs followed a similar trend. Posaconazole consumption showed the largest increase, from from 499 DDDs in 2010-11 (2.1% of total antifungal consumption) to 4907 DDDs (14.6% of total) following the introduction of posaconazole tablets to the formulary in October 2015. In 2016-17, liposomal amphotericin, itraconazole, flucytosine and the echinocandins remained at lower usage compared with 2009-10, with voriconazole and fluconazole at a higher consumption compared with pre-intervention. The proportion of DDDs administered intravenously has reduced from 14% pre-intervention to 10% post-intervention as patients are switched from broadspectrum intravenous antifungals to oral azole therapy.
Whilst OBDs remained constant within the trust during the study period, numbers of patients at risk of IFI rose: admission to the adult ICUs increased substantially (33% increase from 3639 Includes advice on concurrent antibacterial/antiviral therapy (n " 33), managing adverse drug reactions (n " 22) or interactions (n " 3), monitoring response to therapy (n " 17), adjunctive treatment advice (n " 28), escalation/treatment plans (n " 11), prophylaxis post-treatment (n " 5) and follow-up post-discharge (n " 4).
Antifungal stewardship at St George's 
Discussion
To the best of our knowledge, this is the most comprehensive evaluation of an AFS programme to date, providing 6 years' data on stewardship activities alongside clinical and financial outcomes. Our findings demonstrate that an AFS programme has the potential to contain antifungal use and expenditure without adversely affecting patient outcomes, despite increasing numbers of at-risk patients.
Our evaluation was based on reviews of .400 adult patients, including 131 cases of proven IFI. Over half (51%) of patients belonged to the high-risk specialities of haematology and intensive care, representative of a tertiary referral hospital population. Clinical management advice aside, the scope for intervention to stop or limit inappropriate prescribing was high, particularly in those on empirical therapy (82% with no IFI). For haematology Table 3 . Organism, sample and source/focus of infection in proven IFI Organism (n) Sample (n) Source/focus of infection (n)
C. albicans (59) blood culture (25) infective endocarditis (5), line (6), abdominal (2), urinary source (5), unknown (7) pus/fluid (20) abdominal (17), endovascular graft infection (1), pleural effusion post-CABG (1), renal abscess (1) CSF (1) device-associated ventriculitis (1) tissue (13) abdominal (3), prosthetic joint (3), endovascular graft infection (3), mediastinitis (1), sternal wound infection (1), urinary tract (1), alveolar proteinosis, with underlying fungal infection (1) Candida dublinensis (3) blood culture (2) abdominal (1), line (1) pus/fluid (1) abdominal (1) C. glabrata (25) blood culture (21) infective endocarditis (2), line (3), abdominal (6), urinary source (2), unknown (8) pus/fluid (2) abdominal (2) tissue (2) abdominal (1), mediastinitis (1) Candida guilliermondii (1) fluid (1) abdominal C. krusei (2) fluid (2) abdominal (1), unknown (1) Candida lusitaniae (2) blood culture (2) abdominal (2) Candida parapsilosis (4) blood culture (3) abdominal (1), urinary source (1), unknown (1) tissue (1) endovascular infection Candida tropicalis (7) blood culture (5) abdominal (1), line (1), unknown (2), urinary (1) pus/fluid (2) CNS (1), abdominal (1) Candida sp. (1) pus neurosurgical site infection (metal plate in situ) Aspergillus flavus (1) tissue rhino-orbital/CNS Aspergillus fumigatus (5) pus ( Whitney et al.
patients on prophylaxis, a class switch from high-cost intravenous antifungals to azoles was recommended in 44/105 (42%) reviews. Compared with the small pre-intervention audit, significant improvements were demonstrated with respect to de-escalation and stopping in those without IFI and performance of TDM. In its first 3 years, the St George's AFS programme substantially reduced annual antifungal spending (.£300 000, a 30% decrease from baseline).Since 2014, spend has increased, with expenditure reaching £1.2 million in 2016-17 (20% higher than 2009-10). Inflation notwithstanding, this rise is modest compared with UK-wide expenditure, which more than doubled over the same timeframe. Moreover, this occurred in the context of increasing numbers of patients at risk of IFI in the organization during this period, with a 40% expansion of OBDs in intensive care, an 85% increase in stem cell transplants and a 20% increase in chemotherapy courses administered over this period. These figures demonstrate the importance of incorporating denominator data as a surrogate for numbers of at-risk patients in comparisons of antifungal spend either longitudinally or between hospitals. Unsurprisingly, stewardship resulted in more laboratory tests and Antifungal stewardship at St George's JAC increased expenditure on this; however, the mean annual expenditure of £14900 is outweighed by the savings made on antifungal drugs.
In the published literature, we found relatively few articles describing the implementation and impact of AFS programmes, often limited to specific settings (haematology 17 or intensive care 24 ) or infection types (invasive candidiasis) 14, 16 rather than encompassing a hospital-wide approach. Only three papers from France, Spain and the UK describe comprehensive programmes similar to ours, directed at treatment of all IFIs and selected prophylaxis, 15, 18, 20 of which just two employ the 'gold standard' multidisciplinary approach with stewardship rounds as their core component. 15, 20 Our programme is unique amongst the published literature in reporting on all six suggested performance measures: antifungal expenditure and usage, adherence to therapeutic advice, mortality, incidence of IFI and quality of care (length of stay). 25 The Spanish programme achieved a comparable reduction in overall antifungal consumption over 3 years (20% versus 26%) and a cost saving of a similar order of magnitude to ours [US$370682 over 12 months 18 versus £330000 (US$450000) over 3 years in our programme]. The other hospital-wide programme, reported from a tertiary hospital in Cambridge, UK, 20 achieved a comparable percentage reduction in antifungal expenditure over the first year (9.8% versus 11%), on a background of a higher baseline expenditure (£1835000 versus £928000). Our intervention rate was higher overall than the French programme (68% versus 54%), but similar to that in the Cambridge programme (72%) and was sustained across the 6 year programme with consistently high acceptance rates (.80% each year).
Our study has several limitations. This was a single-centre study and the results may not be generalizable to hospitals with a different case mix. Adverse effects of antifungals and re-admission rates were not assessed. The only costs analysed were drug costs-we did not account for costs of laboratory diagnostics or hospital stay-although the median length of stay did not change over time. Whilst mortality in patients reviewed remained stable and appeared lower than in the pre-intervention audit, the observational nature of our study precludes an assessment of the impact of our AFS programme on mortality attributable to IFI. We did not formally assess the costs of the stewardship programme; however, it typically took 3 h of antimicrobial pharmacist time and 2 h of ID consultant time per week.
Key challenges for any stewardship programme are delays in reviewing patients due to frequency of ward rounds, currently only weekly at St George's, and access to timely diagnostic results. Although St George's is a large teaching hospital with a sizeable atrisk population, to date the fungal biomarkers galactomannan and b-D-glucan, fungal PCR and Candida susceptibility testing (excluding fluconazole) are sent to the national reference laboratory, with a median TAT of just under 2 weeks for galactomannan and b-D-glucan. Whilst we have access to same-day radiological investigations (high-resolution chest CT), bronchoscopy and bronchoalveolar lavage for high-risk patients is only available weekly for non-ICU patients. All of these factors limit our opportunity to impact prescribing decisions in real time, particularly stopping unnecessary empirical therapy. There is clear scope to improve the proportion of our patients with no evidence of IFI who had their antifungals stopped within a week (62%). We are currently piloting the impact on antifungal prescribing of introducing b-D-glucan testing in patients at risk of invasive candidiasis in intensive care, in particular its impact on curtailing empirical echinocandin therapy in those without IFI. Of note, non-availability of rapid diagnostics and lack of resources (staff time) were two of the most frequent factors highlighted as a barrier to AFS in the recent English survey. 7 The need for AFS is more pressing than ever as antifungal resistance emerges as a significant threat 13 with outbreaks of Candida auris and increasing reports of MDR C. glabrata and azoleresistant Aspergillus spp. 12 The recently updated IDSA guidelines on antibiotic stewardship for the first time suggest implementation of interventions to improve the appropriate prescribing of antifungal treatment, advising that antibiotic stewards must develop expertise in antifungal therapy and fungal diagnostics for programmes to be successful. 26 AFS also represents a significant opportunity to reduce unnecessary expenditure on high-cost medicines in austerity measures within the UK NHS. In England the majority of antifungal costs are not included within in-patient tariffs, and so are paid for by NHS England, with currently few incentives to encourage individual hospitals to prioritize this issue. This was confirmed by a recent survey of English acute hospital trusts (n " 47 responses), revealing that whilst 98% of trusts had antimicrobial stewardship programmes, only 5 (11%) had a dedicated AFS programme, 7 illustrating an important gap that the NHS England Improving Value Project 27 seeks to address by introduction of financial incentives for implementation of AFS.
In summary, we demonstrate that an AFS programme is readily implementable and sustainable over 6 years, offering a large scope for targeted intervention to prevent unnecessary prescribing, with good clinician acceptance and no compromise of clinical outcomes. Containment of expenditure compared with the national picture and in the face of rising at-risk populations was possible using only 2-3 h of consultant and senior pharmacist time each week. Future challenges for AFS programmes such as ours include lack of access to rapid turnaround and accurate 'rule-out' diagnostics. Globally, AFS remains a poor relation of antibiotic stewardship programmes. To contain rising costs and the emergence of antifungal resistance, national initiatives are urgently needed to harmonize laboratory diagnostics in mycology and to encourage implementation of AFS by a greater proportion of English NHS hospitals.
